Filtered By:
Management: Marketing
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 200 results found since Jan 2013.
Johnson and Johnson Medical Devices Companies Signals Commitment to Stroke Treatment With the Announcement of New Neurovascular Business
NICE, France, September 7, 2017 -- (Healthcare Sales & Marketing Network) -- Johnson & Johnson Medical Devices Companies* today introduced CERENOVUS,** its new neurovascular business, at the European Society of Minimally Invasive Neurological Therapy (ESM... Devices, Neurology, Interventional Johnson & Johnson, CERENOVUS, neurovascular
Source: HSMN NewsFeed - September 7, 2017 Category: Pharmaceuticals Source Type: news
IRRAS Appoints Fredrik Alpsten as Chief Financial Officer and Deputy CEO
Mr. Alpsten will Lead the Development of IRRAS' Global Finance Strategies
STOCKHOLM, Aug. 30, 2017 -- (Healthcare Sales & Marketing Network) -- IRRAS, a commercial-stage medical technology company developing breakthrough devices for a broad range of in... Devices, Neurosurgery, Monitoring, Personnel IRRAS, IRRAflow, stroke, ICP , intracranial bleeding
Source: HSMN NewsFeed - August 30, 2017 Category: Pharmaceuticals Source Type: news
Redivus Health Recognized as Finalist in Fierce Innovation Awards: Healthcare
OLATHE, Kan. — Redivus Health announced that the company has been selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition 2017, an awards program from the publisher of FierceHealthcare. Redivus Health was recognized as one of three finalists in the Clinical Information Management category.
Redivus Health was selected as a finalist for its innovative, industry-leading product, which improves patient care by providing physicians, nurses and paramedics with actionable, clinical guidance during a critical care event. The Redivus mobile application, combined with a cloud-based platform, deliver...
Source: JEMS: Journal of Emergency Medical Services News - August 11, 2017 Category: Emergency Medicine Authors: Revidus Health Tags: Industry News Administration and Leadership Source Type: news
Silk Road Medical Announces $47 Million Financing led by Norwest Venture Partners and Funds Managed by Janus Capital Management LLC
Financing to Support Rapid Growth of TransCarotid Artery Revascularization (TCAR) Procedure
SUNNYVALE, Calif., July 18, 2017 -- (Healthcare Sales & Marketing Network) -- Silk Road Medical, Inc., a company dedicated to alleviating the devastating burden... Devices, Interventional, Radiology, Venture Capital Silk Road Medical, ENROUTE, TransCarotid Artery Revascularization, stroke
Source: HSMN NewsFeed - July 18, 2017 Category: Pharmaceuticals Source Type: news
Sensome, Formerly Instent, Raises 4.7m to Bring the World's First Connected Stroke Guidewire to Patients
Sensome's first application of its AI-powered micro-sensor technology can detect the composition of the blockage in the brain during stroke treatment
PARIS, July 17, 2017 -- (Healthcare Sales & Marketing Network) -- Sensome, formerly Instent, a company... Devices, Interventional, Venture Capital Sensome, Instent , guidewire, stroke
Source: HSMN NewsFeed - July 17, 2017 Category: Pharmaceuticals Source Type: news
Zynex Hires Chief Financial Officer
LONE TREE, Colo., June 9, 2017 -- (Healthcare Sales & Marketing Network) -- Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilita... Devices, Neurology, Personnel Zynex, electrotherapy
Source: HSMN NewsFeed - June 9, 2017 Category: Pharmaceuticals Source Type: news
Ex-Invacare chief Mixon pulls the trigger on convertible shares
Invacare (NYSE:IVC) said yesterday that the former chairman & CEO who rescued the company from the doldrums in the 1980s, Malachi Mixon III, is pulling the trigger on the more than 700,000 convertible shares he controls.
The 1-for-1 exchange will take Invacare’s voting power from 40,155,366 votes to 33,820,158 votes, the Elyria, Ohio-based company said.
“The conversion will substantially diminish the significance of the company’s dual class voting structure, as after completion, the holders of the common shares will represent approximately 99.5% of the company’s total outstanding voting power,...
Source: Mass Device - June 1, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Wall Street Beat Invacare Rehabilitation Equipment Source Type: news
CytoSorbents touts Refresh trial study data
CytoSorbents (OTC:CTSO) today presented results from the Refresh trial of its CytoSorb blood purification technology, touting that the trial met its safety goals and that treatment reduced toxic inflammatory mediators during complex heart surgery.
Data was presented at the American Association for Thoracic Surgery’s centennial conference in Boston this week.
The Monmouth Junction, N.J.-based company’s CytoSorb is an extracorporeal cytokine filter, made up of biocompatible, porous polymer beads that use pore capture and surface adsorption to remove toxic substances from the blood and other bodily fluids.
The pr...
Source: Mass Device - May 5, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Blood Management Clinical Trials CytoSorbents Corp. Source Type: news
Criteria for the choice of anticoagulant therapy for the prevention of stroke in patients with atrial fibrillation early after the marketing of direct oral anticoagulants in Italy.
PMID: 28476324 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - May 2, 2017 Category: Internal Medicine Authors: Marzona I, Roncaglioni MC, Avanzini F, Franzosi MG, Moia M, members of an ad hoc study group Tags: Eur J Intern Med Source Type: research
Blood pressure control with cilnidipine treatment in Japanese post-stroke hypertensive patients: The CA-ATTEND study.
Abstract
Blood pressure control is important in post-stroke hypertensive patients and antihypertensive treatment is recommended for such patients. Ca-channel blockers are recommended as the medications of choice for the treatment of post-stroke patients. Here, we report the results of a large-scale prospective post-marketing surveillance study of post-stroke hypertensive patients (n = 2667, male 60.4%, 69.0 ± 10.9 years) treated with cilnidipine, with regard to blood pressure control and adverse reactions. Cilnidipine treatment caused a decrease in both clinic and home blood pressures 2 months after the beginning...
Source: Clinical and Experimental Hypertension - April 29, 2017 Category: Cardiology Authors: Aoki S, Hosomi N, Nezu T, Teshima T, Sugii H, Nagahama S, Kurose Y, Maruyama H, Matsumoto M Tags: Clin Exp Hypertens Source Type: research
Codman Neuro Announces Acquisition Of Neuravi Limited To Accelerate Innovation In Acute Ischemic Stroke Therapy
Second Acquisition in Months Demonstrates Commitment to Addressing Unmet Needs in Stroke
IRVINE, Calif., April 10, 2017 -- (Healthcare Sales & Marketing Network) -- Codman Neuro today announced the acquisition of Neuravi Limited, a privately held Irish... Devices, Neurology, Interventional, Mergers & Acquisitions Codman, Johnson & Johnson, Neuravi Limited, EmboTrap, stroke
Source: HSMN NewsFeed - April 10, 2017 Category: Pharmaceuticals Source Type: news
New Study Shows Prevencios Simple Blood Test Determines Risk of Heart Attack, Stroke, or Cardiovascular Death
KIRKLAND, Wash.--(Healthcare Sales & Marketing Network)--Prevencio, Inc. today announces the presentation of data which demonstrate that a simple blood test is more accurate than commonly-used risk factors in determining whether a person will have a heart ... Diagnostics, Cardiology Prevencio, HART CVE, HART CAD
Source: HSMN NewsFeed - March 17, 2017 Category: Pharmaceuticals Source Type: news
Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients
AbstractAcute ischemic stroke (AIS) is a major medical challenge in China. Thrombolytic drugs recommended for the treatment of AIS usually have a narrow time window. Human urinary kallidinogenase (HUK) was approved by the China Food and Drug Administration (CFDA) in 2005 for the treatment of mild to moderate AIS, and it is thus widely used in China. However, large-scale clinical study data for a more complete understanding of various aspects of its safety and efficacy characteristics are still unavailable. The ongoing Reevaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK) trial is designed to reevaluate...
Source: Translational Stroke Research - March 5, 2017 Category: Neurology Source Type: research
Keystone Heart, Venus Medtech ink Asian TAVR stroke partnership deal
Keystone Heart and Chinese heart valve maker Venus Medtech said today they inked a partnership deal covering China and other Asian markets.
Through the deal, the companies will provide Venus Medtech’s transcatheter aortic valve replacement system along with Keystone’s TriGuard cerebral embolic protection device.
TriGuard is a cerebral embolic protection device designed to reduce the amount of embolic material entering blood circulation to the brain during TAVR procedures, by allowing blood to pass through while catching potentially dangerous embolic debris.
“Providing brain protection for every TAVR pat...
Source: Mass Device - March 2, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular Catheters Replacement Heart Valves Keystone Heart Venus Medtech Source Type: news
